- Home
- GIB vs MDGL Comparison
GIB vs MDGL Comparison
Compare GIB & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GIB | MDGL |
|---|---|---|
| Founded | 1976 | 2011 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.8B | 12.4B |
| IPO Year | 1999 | 2005 |
Fundamental Metrics
Financial Performance| Metric | GIB | MDGL |
|---|---|---|
| Price | $68.03 | $558.84 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 12 |
| Target Price | $112.00 | ★ $674.45 |
| AVG Volume (30 Days) | ★ 485.7K | 307.9K |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.70% | N/A |
| EPS Growth | N/A | ★ 41.32 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $180,133,000.00 |
| Revenue This Year | $8.33 | $58.39 |
| Revenue Next Year | $2.96 | $48.55 |
| P/E Ratio | $13.59 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $59.63 | $286.75 |
| 52 Week High | $103.04 | $615.00 |
Technical Indicators
Market Signals| Indicator | GIB | MDGL |
|---|---|---|
| Relative Strength Index (RSI) | 56.82 | 61.55 |
| Support Level | $60.78 | $498.59 |
| Resistance Level | $69.13 | $570.82 |
| Average True Range (ATR) | 1.75 | 23.15 |
| MACD | 0.35 | 1.56 |
| Stochastic Oscillator | 88.36 | 82.00 |
Price Performance
Historical ComparisonAbout GIB CGI Inc.
CGI is a Canada-based IT-services provider with an embedded position in North America and Europe. The company is one of the major IT suppliers to different levels of government around the world. It offers a broad portfolio of services such as consulting, systems integration, application maintenance, and business process services to governments and the private sector. With offices in over 40 countries, CGI follows a balanced global delivery model with most consultants in client proximity.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.